skip to navigation skip to content



LIFNano honoured in Berlin

LIFNanoRX, a venture that targets multiple sclerosis (MS) and supported by Cambridge Judge, is named Most Promising Nanomedicine Project at the annual BIO-Europe conference.

LifNano honoured in Berlin : multicoloured star background

Dr Su Metcalfe

Dr Su Metcalfe

LIFNanoRX, a venture supported by Cambridge Judge Business School that seeks to halt the development of multiple sclerosis, was named Most Promising Nanomedicine Project at the annual BIO-Europe international partnering conference in Berlin.

Founded by Dr Su Metcalfe, LIFNano deploys nanoparticles to trigger natural healing in the brain using Leukaemia inhibitory factor (LIF), where LIF acts to counter the disease process as it attacks the brain and spinal cord. Su, who earned a PhD in pathology at the University of Cambridge, launched LIFNano in 2013.

LIFNano is currently on the Accelerate Cambridge programme run by the Cambridge Judge Entrepreneurship Centre, and previously was supported by the Cambridge Social Ventures programme run by the Cambridge Centre for Social Innovation at Cambridge Judge.

The Nanomedicine Awards announced in Berlin are organised by the European Technology Platform and EU-funded ENATRANS project. The awards honour firms that have developed a nanomedicine solution “that could bring large benefits to patients, changing the way diseases are treated or diagnosed or providing new tools for physicians.”

In a presentation at the awards ceremony, Su explained that stem cells release LIF, and LIF then turns on the body’s own healing power. Nanotechnology harnesses LIF directly, without the need for stem cells, both to treat the brain and to turn off the autoimmunity that drives MS. Clinical trials are planned for 2020.